Summary
3.53 -0.50(-12.41%)09/06/2024
Virax Biolabs Group Limited Ordinary Shares (VRAX)
Virax Biolabs Group Limited Ordinary Shares (VRAX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -12.41 | -2.40 | 3.36 | -37.30 | -38.59 | -83.16 | 0.00 | 0.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.53 | |
| Open | 3.96 | |
| High | 4.26 | |
| Low | 3.53 | |
| Volume | 1,481,763 | |
| Change | -0.50 | |
| Change % | -12.41 | |
| Avg Volume (20 Days) | 51,777 | |
| Volume/Avg Volume (20 Days) Ratio | 28.62 | |
| 52 Week Range | 0.22 - 1.71 | |
| Price vs 52 Week High | 106.43% | |
| Price vs 52 Week Low | 1,528.98% | |
| Range | 0.00 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 15 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -24.5352 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 109,820 | |
| Revenue per share TTM | 0.0180 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -9,434 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 1,133.8641 | |
| EBITDA Enterprise Value | -45.1687 | |
| Shares | ||
| Shares Outstanding | 11,374,100 | |
| Shares Float | 4,042,997 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 61.77 | |
| Institutions (%) | 0.00 | |
08/29 09:03 EST - prnewswire.com
Virax Biolabs to Participate at 7th European Congress of Immunology
LONDON , Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland. The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.
Virax Biolabs to Participate at 7th European Congress of Immunology
LONDON , Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland. The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.
08/28 14:18 EST - invezz.com
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know
Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations.
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know
Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations.
08/28 07:30 EST - prnewswire.com
Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East
LONDON , Aug. 28, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in 13 European countries as well as members of the Gulf Cooperation Council ("GCC") including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom.
Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East
LONDON , Aug. 28, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in 13 European countries as well as members of the Gulf Cooperation Council ("GCC") including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom.
08/23 16:09 EST - prnewswire.com
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
LONDON , Aug. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
LONDON , Aug. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
08/21 21:30 EST - prnewswire.com
Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares
LONDON , Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about August 23, 2024, subject to the satisfaction of customary closing conditions.
Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares
LONDON , Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about August 23, 2024, subject to the satisfaction of customary closing conditions.
08/21 10:20 EST - accesswire.com
Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today, pursuant to its agreement with Virax Biolabs (NASDAQ: VRAX), that it continues to hold the rights to distribute mpox virus real-time PCR detection kits, with exclusive distribution rights in Greece and Cyprus, and non-exclusive distribution rights across Europe. On August 14, 2024, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations.
Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today, pursuant to its agreement with Virax Biolabs (NASDAQ: VRAX), that it continues to hold the rights to distribute mpox virus real-time PCR detection kits, with exclusive distribution rights in Greece and Cyprus, and non-exclusive distribution rights across Europe. On August 14, 2024, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations.
08/19 12:11 EST - zacks.com
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
06/07 08:31 EST - investorplace.com
Why Is Virax Biolabs (VRAX) Stock Down 15% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is down on Friday after the biotechnology company's shares underwent a massive rally yesterday. That saw shares of VRAX stock close out the prior day of trading up 85.8%.
Why Is Virax Biolabs (VRAX) Stock Down 15% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is down on Friday after the biotechnology company's shares underwent a massive rally yesterday. That saw shares of VRAX stock close out the prior day of trading up 85.8%.
06/06 07:55 EST - investorplace.com
Why Is Virax Biolabs (VRAX) Stock Up 115% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is rocketing higher on Thursday morning alongside heavy pre-market trading of the biotechnology company's shares. The heavy trading of Virax Biolabs stock has more than 15.2 million shares trading hands as of this writing.
Why Is Virax Biolabs (VRAX) Stock Up 115% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is rocketing higher on Thursday morning alongside heavy pre-market trading of the biotechnology company's shares. The heavy trading of Virax Biolabs stock has more than 15.2 million shares trading hands as of this writing.
04/25 08:00 EST - prnewswire.com
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
LONDON , April 25, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmune™ T-Cell diagnostic platform for research-use-only ("RUO"), at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress, which is taking place from April 27th to April 30th, 2024, in Barcelona, Spain. The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
LONDON , April 25, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmune™ T-Cell diagnostic platform for research-use-only ("RUO"), at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress, which is taking place from April 27th to April 30th, 2024, in Barcelona, Spain. The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
04/16 07:30 EST - prnewswire.com
Virax Biolabs to Participate at ESCMID Global 2024
LONDON , April 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) on April 27-30, 2024, in Barcelona, Spain. The Company will be showcasing its portfolio of products for research use at Booth F43, and management will be available for discussions with research organizations and potential customers.
Virax Biolabs to Participate at ESCMID Global 2024
LONDON , April 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) on April 27-30, 2024, in Barcelona, Spain. The Company will be showcasing its portfolio of products for research use at Booth F43, and management will be available for discussions with research organizations and potential customers.
03/15 16:30 EST - prnewswire.com
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
LONDON , March 15, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
LONDON , March 15, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
12/27 16:57 EST - pennystocks.com
Penny Stocks To Buy Before 2024? 3 For Your Watch List Now
Penny stocks, defined as stocks that trade for less than $5 per share, can be appealing to investors due to their low prices and potential for large percentage gains. However, penny stocks also carry more risk than regular stocks.
Penny Stocks To Buy Before 2024? 3 For Your Watch List Now
Penny stocks, defined as stocks that trade for less than $5 per share, can be appealing to investors due to their low prices and potential for large percentage gains. However, penny stocks also carry more risk than regular stocks.
12/21 07:30 EST - prnewswire.com
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
LONDON , Dec. 21, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust, who have a track record in working together to deliver translational immunology research for respiratory viral infections. This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
LONDON , Dec. 21, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust, who have a track record in working together to deliver translational immunology research for respiratory viral infections. This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
12/18 07:30 EST - prnewswire.com
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON , Dec. 18, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders that provides an update on recent events and an outlook for 2024.
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON , Dec. 18, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders that provides an update on recent events and an outlook for 2024.
12/14 07:30 EST - prnewswire.com
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
LONDON , Dec. 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the annual general meetings of the shareholders held on Wednesday, December 6, 2023, at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, approved the proposed 1-for-10 share consolidation of its ordinary shares of US$0.0001 par value each (the "Share Consolidation"). Beginning with the opening of trading on December 18, 2023, the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "VRAX", but under a new CUSIP number of G9495L125.
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
LONDON , Dec. 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the annual general meetings of the shareholders held on Wednesday, December 6, 2023, at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, approved the proposed 1-for-10 share consolidation of its ordinary shares of US$0.0001 par value each (the "Share Consolidation"). Beginning with the opening of trading on December 18, 2023, the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "VRAX", but under a new CUSIP number of G9495L125.
09/12 07:30 EST - prnewswire.com
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
LONDON , Sept. 12, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of an early access program for the research-use-only ("RUO") of its proprietary SARS-Cov-2 ViraxImmune T-cell-based test.
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
LONDON , Sept. 12, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of an early access program for the research-use-only ("RUO") of its proprietary SARS-Cov-2 ViraxImmune T-cell-based test.
09/01 07:30 EST - prnewswire.com
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
LONDON , Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO").
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
LONDON , Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO").
08/03 09:43 EST - investorplace.com
Why Is Virax Biolabs (VRAX) Stock Up Today?
Virax Biolabs (NASDAQ: VRAX ) stock is on the rise Thursday as investors react to the news on an extension from the Nasdaq Exchange. According to a press release from the diagnostics test kits maker, the Nasdaq is giving it an additional 180 days to regain compliance.
Why Is Virax Biolabs (VRAX) Stock Up Today?
Virax Biolabs (NASDAQ: VRAX ) stock is on the rise Thursday as investors react to the news on an extension from the Nasdaq Exchange. According to a press release from the diagnostics test kits maker, the Nasdaq is giving it an additional 180 days to regain compliance.
08/03 07:30 EST - prnewswire.com
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
LONDON , Aug. 3, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today that Nasdaq has approved the Company's request for a 180-day extension to meet the $1 minimum bid price requirement. On January 30, 2023, Nasdaq provided notice to the Company that based on the previous 30 consecutive business days, the Company's listed common stock no longer met the minimum $1 bid price per share requirement as set forth in Nasdaq Listing Rule 5810(c)(3)(A)(ii).
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
LONDON , Aug. 3, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today that Nasdaq has approved the Company's request for a 180-day extension to meet the $1 minimum bid price requirement. On January 30, 2023, Nasdaq provided notice to the Company that based on the previous 30 consecutive business days, the Company's listed common stock no longer met the minimum $1 bid price per share requirement as set forth in Nasdaq Listing Rule 5810(c)(3)(A)(ii).